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Polycyclic aromatic hydrocarbons (PAHs) likely play a role in many cancers even in never-smokers. We tried to find a model
to explain the relationship between variation in PAH-related DNA adduct levels among people with similar exposures,
multiple genetic polymorphisms in genes related to metabolic and repair pathways, and nucleotide excision repair (NER)
capacity. In 111 randomly selected female never-smokers from the Golestan Cohort Study in Iran, we evaluated 21 SNPs in
14 genes related to xenobiotic metabolism and 12 SNPs in eight DNA repair genes. NER capacity was evaluated by a
modified comet assay, and aromatic DNA adduct levels were measured in blood by 32P-postlabeling. Multivariable regression
models were compared by Akaike’s information criterion (AIC). Aromatic DNA adduct levels ranged between 1.7 and 18.6 per
108 nucleotides (mean: 5.8 6 3.1). DNA adduct level was significantly lower in homozygotes for NAT2 slow alleles and
ERCC5 non-risk-allele genotype, and was higher in the MPO homozygote risk-allele genotype. The sum of risk alleles in
these genes significantly correlated with the log-adduct level (r 5 0.4, p < 0.001). Compared with the environmental model,
adding Phase I SNPs and NER capacity provided the best fit, and could explain 17% more of the variation in adduct levels.
NER capacity was affected by polymorphisms in the MTHFR and ERCC1 genes. Female non-smokers in this population had
PAH-related DNA adduct levels three to four times higher than smokers and occupationally-exposed groups in previous
studies, with large inter-individual variation which could best be explained by a combination of Phase I genes and NER
capacity.
Polycyclic aromatic hydrocarbons (PAHs) are a class of car-
cinogens which are produced mainly by incomplete fuel
combustion.1 There are several studies documenting a possi-
ble role for PAH exposure in the etiology of esophageal
squamous cell carcinoma (ESCC).2–7 In a recent report from
Golestan Province, Iran, a high risk area for ESCC, Abedi-
Ardekani et al. showed a striking dose-response relationship
between the PAH content of non-tumoral esophageal biop-
sies, measured by immunohistochemical staining with anti-
bodies raised against benzo[a]pyrene diol epoxide-I-modiﬁed
guanosine, and ESCC case status.2 Studies in this area and
other high risk areas for ESCC in Brazil and along the
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central Asian esophageal cancer belt have also shown high
exposures to PAHs.3–4,6 This high exposure has been
observed among non-smokers as well as smokers, and food
and coal-burning stoves have been suggested as potential
sources.3,5,7,8 Similarly, exposure to PAH has also been
implicated in lung cancer pathogenesis in non-smokers.9
Many PAHs do not cause biological changes by
themselves, but do so only after being converted to active
metabolites in the body.10 PAHs are ﬁrst metabolized to
more polar compounds by Phase I enzymes. As a result of
these reactions, reactive electrophilic intermediates may be
formed that can bind to DNA to form DNA adducts, which
are responsible for the mutagenic effects of PAHs; or they
may be further metabolized by Phase II enzymes that conju-
gate these electrophilic metabolites to form water-soluble
compounds that can be excreted. DNA adduct formation is,
in fact, an early biological event in the carcinogenic
process.11 DNA repair mechanisms, including nucleotide
excision repair (NER), can restore the integrity of the dam-
aged parts of DNA.12
While differences in environmental exposures are partly
responsible for variations in DNA adduct formation, inter-
individual variations among people with similar exposures
may be explained partially by polymorphisms in genes that
code for metabolizing or repair enzymes,10 and accumulating
evidence suggests a role for genetic polymorphisms in PAH-
related DNA adduct formation.13 So far, however, the results
have been inconsistent regarding the roles of single polymor-
phisms, and many researchers now suggest that, due to the
complex exposure and nature of PAH metabolism, a combi-
nation of genes in this metabolic pathway should instead be
considered.10 For example, it has been shown that the sum of
risk alleles in multiple PAH-metabolizing genes can affect
adduct levels in smokers.14
In this study, we evaluated a large number of polymor-
phisms in genes affecting DNA adduct formation and repair,
along with NER phenotyping, in Golestan Province, a high-
risk area for ESCC in northeastern Iran. Our main purpose
was to identify the best models to explain inter-individual
variations in adduct levels. Women in this area are not likely
to be exposed to PAHs in an occupational setting, so non-
smoking women constitute a relatively homogenous group in
terms of PAH exposure. We restricted this study to female
non-smokers in order to minimize the variation in adduct
levels due to differences in environmental exposures.
Material and Methods
Sampling
One hundred eleven female non-smokers were randomly
selected from subjects recruited in the Golestan Cohort Study
(GCS), details of which have been published before.15 Brieﬂy,
50,045 healthy adults from eastern Golestan Province were
recruited into this cohort, including 48% men and 52%
women, 80% from rural villages, and 74% of Turkmen
ethnicity. Questionnaire data were collected about exposure
to second-hand smoke at work or home; cooking methods in
the household, including frying, boiling, baking, and barbequ-
ing; as well as the frequency of coal use for cooking. A stand-
ard food frequency questionnaire was administered, and the
amounts of total and processed red meat consumption were
calculated as potential sources of PAH.
Venous blood was collected from study participants, cen-
trifuged at 800g for 20 min, and the buffy coat was separated
and stored at 70C. After destroying RBCs using a lysis
buffer (155 mmol/L NH4Cl, 10 mmol/L KHCO3, and 10
mmol/L EDTA), genomic DNA was extracted from the buffy
coat by standard phenol extraction and stored in 70C until
genotyping and 32P-postlabeling. For the NER assay, lympho-
cytes were isolated from venous blood using a standard
density gradient centrifugation method16 and stored at
70C. A single spot urine sample was collected from each
participant and stored at 20C.
The study was approved by the Institutional Review Board
of the Digestive Disease Research Center of Tehran Univer-
sity of Medical Sciences.
Genotyping
Twenty-one SNPs in 14 genes related to xenobiotic metabo-
lism and 12 SNPs in eight DNA repair genes were studied
(Table 1). SNP’s were selected on the basis of (i) their associ-
ation with PAH metabolism and/or cancer development or
(ii) their expected inﬂuence on DNA repair activity.17 These
included genes for Phase I metabolizing enzymes: cytochrome
P450s (CYP1A1, CYP1A2, CYP1B1, CYP2E1, and CYP3A4),
microsomal epoxide hydrolase 1 (mEH), and myeloperoxi-
dase (MPO); genes for Phase II enzymes: glutathione peroxi-
dase 1 (GPX1), glutathione S-transferases (GSTM1, GSTP1,
GSTT1), N-acetyltransferase 2 (NAT2), NAD(P)H quinone
oxidoreductase 1 (NQO1), and manganese superoxide dismu-
tase 2 (MnSOD2); and genes for DNA repair: apurinic-
What’s new?
Polycyclic aromatic hydrocarbons (PAHs) likely play a role in esophageal squamous cell carcinoma (ESCC) through the
formation of DNA adducts. Variation in adduct formation among people with similar exposures is however not well
understood. Here the authors show that female non-smokers in a population at high risk of ESCC had exceptionally high DNA
adducts, with large inter-individual variations best explained by a combination of PAH phase I metabolizing genes and
nucleotide excision repair (NER) capacity. This study shows the importance of studying a large set of combined
polymorphisms and NER phenotyping together, and sheds light on PAH-related carcinogenesis in non-smokers.
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apyrimidinic endonuclease 1 (APEX1), DNA excision repair
cross-complementing proteins (ERCC1, ERCC5, ERCC6),
methylenetetrahydrofolate reductase (MTHFR), RAD23B, and
the xeroderma pigmentosum group (XPA, XPC).
Genotyping was performed by a SNaPshot procedure as
described earlier18 at the Department of Toxicology, Maas-
tricht University (Maastricht, The Netherlands). Polymerase
chain reaction (PCR) primers were designed using Primer 3
and Netprimer software, as detailed before.14,19 PCR was
done in four separate multiplex reactions: two 10-plex and
two 7-plex (shown as 1–4 in Table 1) on a Tgradient 96-well
thermal cycler (Biometra, Goettingen, Germany), each in a
10-mL volume using 96-well plates. The annealing tempera-
tures were optimized for each multiplex PCR: 56C for multi-
plex 1, 58C for multiplex 2, 60C for multiplex 3, and 60C
for multiplex 4. The PCR products were then incubated
(37C for 45 min) with 4 mL Exo-SAP-IT (Amersham,
Roosendaal, The Netherlands) to digest contaminating deoxy-
nucleotide triphosphates and PCR primers. Enzymes were
deactivated at 75C for 15 min. Subsequently, the single base
Table 1. Details of the genes and polymorphisms evaluated in this study
Set Gene SNP ID Mutation
Putative risk
allele1 (frequency)
HWE
p value
PCR
multiple
Phase I CYP1A1 rs1048943 Ex7þ131A>G G (0.08) 0.4 2
rs1799814 Ex7þ129C>A A (0.05) 0.2 2
CYP1A2 rs762551 IVS1-154C>A A (0.59) 0.03 1
CYP1B1 rs1056836 Ex3þ251G>C C (0.27) 0.6 2
rs1800440 Ex3þ315A>G G (0.20) 0.5 2
CYP2E1 rs6413420 -70T>G G (0.10) 0.3 2
CYP3A4 rs2740574 -391A>G G (0.02) 0.8 2
mEH rs2234922 Ex4þ52A>G A (0.55) 0.1 3
rs1051740 Ex3-28T>C C (0.49) 0.7 3
MPO rs2333227 -642G>A A (0.36) 0.07 2
Phase II GPX1 rs1050450 Ex1-226C>T T (0.24) 0.2 3
GSTM1 Ex4þ10þ>- –/– (0.52) – 1
GSTP1 rs1695 Ex5-24A>G G (0.41) 0.5 1
rs1138272 Ex6þ5C>T C (0.25) 0.9 1
GSTT1 Ex5-49þ>- –/– (0.89) – 1
NAT2 rs1801280 Ex2þ347T>C C (0.57) 0.9 1
rs1799931 Ex2-313G>A A (0.31) 0.9 1
rs1799930 Ex2-580G>A A (0.31) 0.5 1
NQO1 rs1800566 Ex6þ40C>T T (0.09) 0.4 3
rs1131341 Ex4-3C>T T (0.27) 0.6 3
MnSOD2 rs4880 Ex2þ24T>C C (0.18) 0.8 3
Repair APEX1 rs1130409 Ex5þ5T>G G (0.34) 0.07 3
ERCC1 rs11615 Ex4þ33T>C C (0.29) 0.6 4
rs3212948 IVS3þ74C>G G (0.46) 0.4 4
rs3212986 196þSTP T>G G (0.27) 0.8 4
ERCC5 rs1047768 Ex2þ50T>C C (0.33) 0.5 4
ERCC6 rs2228526 Ex18þ219A>G G (0.24) 0.7 4
MTHFR rs1801131 Ex8-62A>C A (0.57) 0.4 1
rs1801133 Ex5þ79C>T T (0.18) 0.2 1
RAD23B rs1805329 Ex7þ65C>T T (0.04) 0.8 4
XPA rs1800975 Ex1þ62A>G G (0.34) 0.6 4
XPC rs2228001 Ex16þ211C>A A (0.50) 0.8 4
rs2228000 Ex9-377C>T T (0.23) 0.7 4
1Alleles which can increase adduct level as evidenced by previous studies or based on their effect on the enzyme activity.
Abbreviations: SNP: single nucleotide polymorphism; PCR: polymerase chain reaction; MAF: minor allele frequency; HWE: Hardy-Weinberg equilibrium.
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extension (SBE) method by SnaPShot (Applied Biosystems,
Nieuwekerk, a.d. IJssel, The Netherlands) was used for geno-
typing. A different multiplex SBE reaction was conducted on
each multiplex PCR product.18 After genotyping, SBE products
were analyzed on an ABI Prism 3100 genetic analyzer using
Genscan Analysis software (version 3.7). Ten percent of the
samples were randomly genotyped in a separate experiment
and results were in 100% agreement with the ﬁrst analysis.
Nucleotide excision repair
The nucleotide excision repair (NER) assay was performed at
the Department of Toxicology, Maastricht University, by a
modiﬁed single-cell alkaline gel electrophoresis (Comet) assay,
which is based on the fact that the rate limiting steps in NER
are the recognition and incision of the damaged DNA.20 The
capacity of the cells in performing these rate limiting steps can
be quantiﬁed through formation of single-strand breaks meas-
ured by the comet assay. The NER capacity of the cell extracts
is reﬂected by increased percentages of ﬂuorescence in the tail
(‘‘comets’’).21 A549 cells (human epithelial lung carcinoma
cells) were trypsinized at 80% conﬂuency and diluted to a con-
centration of 2  106 cells/mL 1 day before the assay. Aliquots
(25 mL) of untreated A549 cells were mixed with 75 mL low
melting point agarose and transferred to microscope slides,
which were pre-coated with 1.5% normal electrophoresis grade
agarose (Sigma–Aldrich, Germany). Slides were lysed over-
night in cold (4C) lysis buffer. On the day of the assay, the
slides were washed and the resulting nucleoids were exposed
to 1 mM benzo[a]pyrene diol expoxide (BPDE) (NCI Chemical
Carcinogen Reference Standard Repository, Midwest Research
Institute, Kansas City, MO) or vehicle control (DMSO, 0.5%)
for 30 min.
The lymphocyte extracts were prepared using the method
developed by Redaelli et al.22 Fifty microliters of this extract
was added to each slide containing BPDE-exposed gel-em-
bedded nucleoids, and incubated for 10 min at 37C. Imme-
diately after the incubation, slides were put on ice to stop the
enzymatic reaction. The slides were further processed accord-
ing to the conventional comet assay.23 In brief, for DNA
denaturation the slides were immersed in electrophoresis
buffer (0.3 M NaOH, 1 mM EDTA, approximately pH 13)
for 20 min, followed by 20 min of electrophoresis (25 V and
300 mA). The slides were neutralized to a pH of 7.4 and
dried. The dried slides were stained with ethidium bromide
(10 mg/mL), and comets were visualized using a Zeiss Axio-
skop ﬂuorescence microscope. On each slide 50 random cells
were analyzed using Comet assay III software (Perceptive
Instruments, Haverhill, UK). After subtracting background
levels from all data, the ﬁnal NER capacity was calculated by
subtracting tail moments of the BPDE-/extractþ (non-
adduct-containing nucleoids incubated with protein extract)
and BPDEþ/extract- (adduct-containing nucleoids exposed to
BPDE only) slides from the BPDEþ/extractþ (adduct-
containing nucleoids incubated with protein extract) slides.
The NER capacity could be measured in only 81 subjects,
because in 30 samples, either the amount of material pro-
vided was not sufﬁcient to reliably measure DNA repair, or
there was visible contamination with red blood cells, which
made it impossible to make a representative cell extract.
Urinary 1-hydroxypyrene glucuronide concentration
The 1-hydroxypyrene glucuronide (1-OHPG) was measured in
spot urine specimens at the Department of Environmental
Health Sciences, Johns Hopkins Bloomberg School of Public
Health (Baltimore, MD).24 Synchronous ﬂuorescence spectros-
copy (Perkin Elmer LS50B Luminescence spectrometer, Nor-
walk, CT) was used with a wavelength difference of 34 nm
between excitation and emission. The limit of detection was 0.01
ng 1-OHPG/mL urine and the assay recovery was 95-100%.
Adduct 32P-postlabeling
32P-postlabeling analysis was carried out using the nuclease
P1 enrichment with some modiﬁcations at the Institute of
Cancer Research (Sutton, UK), as described previously.25
Brieﬂy, DNA (4 mg) was digested using micrococcal endonu-
clease (0.25 U/mL) and spleen phosphodiesterase (2 mg/mL)
for 3.5 hr at 37C. DNA digests were treated with nuclease
P1 (0.96 mL, 1.25 mg/mL) for 1 hr at 37C. To stop the nu-
clease P1-reaction, 1.92 mL Tris base (pH 9.6) was added.
Labeling of PAH-modiﬁed nucleotides was done with
[c-32P]ATP plus polynucleotide kinase (PNK) (6 U) for 30
min at 37C. The radiolabeled adducted nucleotide bisphos-
phates were separated on PEI-cellulose sheets (Machery
Nagel, Duren, Germany) by multidirectional thin layer chro-
matography (TLC). A standard with known levels of ben-
zo[a]pyrene diol-epoxide(BPDE)-DNA adducts was analyzed
in parallel for quantiﬁcation purposes. Quantiﬁcation was
performed using an InstantImager (Canberra Packard, Dow-
ers Grove, IL, USA). Assays were done in duplicate (or in
triplicate when necessary) and the averages are reported. The
assay coefﬁcient of variation (CV) was 11.7% for the raw
data and 10.2% for the log-transformed values.
Statistical analysis
Descriptive data are presented as mean 6 standard deviation,
and median (interquartile range: IQR). Allele and genotype
frequencies were calculated for all SNPs and tested for
Hardy-Weinberg equilibrium (Table 1). Since adduct levels,
NER capacity, and the urinary 1-OHPG did not have normal
distributions and were positively skewed, they were logarith-
mically transformed before being used in the analyses.
SNPs in the same gene were in linkage disequilibrium, as
most D’ statistics were >0.9 (Supporting Information Table 1).
Polymorphism data were coded using a gene-based approach.
First, for each SNP, using the functional information in the lit-
erature,17,26 the alleles potentially enhancing adduct formation
(risk alleles) were determined (Table 1). The ‘‘risk-allele score’’
was calculated for each gene in the following way: if at least
one of the SNPs in a gene was homozygous for the risk allele,
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the gene was coded 2; if at least one of the SNPs was hetero-
zygous and none were homozygous for the risk allele, it was
coded 1; and if all the SNPs in the same gene had low-risk al-
leles, it was coded as having 0 risk alleles. For the NAT2 gene,
the same scoring was used based on having a genotype with
zero, one or two slow acetylation alleles in any of the three
SNPs studied.27 For GSTM1 and GSTT1, deletion, which
results in the absence of the enzyme, was coded 2 (as opposed
to 0 for those with the enzyme present).
In order to analyze the effect of individual genes, both
univariate and multivariate methods were used. For univari-
ate analyses, we used one-way analysis of variance to com-
pare log-transformed adduct levels and NER capacity
between individuals with different numbers of risk alleles.
For multivariate analyses, a backward stepwise regression
analysis was used. Log-transformed adduct levels were mod-
eled against xenobiotic and repair genes (coded as described
above) and the environmental factors (age, ethnicity, place of
residence, passive smoking, red and processed meat intake,
cooking method and coal use). Each group of genes (Phase I,
Phase II, and repair) was also adjusted for the sum of risk al-
lele scores in the other groups.
Full models were compared to determine the best model
to explain inter-individual variation in DNA adduct levels.
The base model included only the selected environmental
factors. Other models were built by adding one component
at a time to the base model (1-OHPG, Phase I genes, Phase
II genes, repair genes, and NER capacity). Models were com-
pared using Akaike’s information criteria (AIC):
AIC ¼ 2 log LðhÞ þ 2k
where L(y) is the maximized likelihood function and k is the
number of parameters in the model. In other words, AIC
adds twice the number of parameters to the likelihood of the
model as a penalty for overﬁtting. Lower AIC indicates a bet-
ter ﬁt for the model.28
Spearman correlation was used to assess the linear correla-
tion between the number of risk alleles and the log-adduct lev-
els. HaploStats R package was used to build regression models
with haplotypes as predictors and log-adducts or log-NER as
outcomes. Haplotypes which met these two criteria were used
in the models: high linkage disequilibrium (D’ > 0.9 or r2 >
0.8) among the alleles, and a haplotype prevalence of at least
2%. We used Stata 11.2 (StataCorp LP, TX) and snpStats R
package version 1.2.1 for analyses. A two-sided p value of less
than 0.05 was considered to be signiﬁcant.
Results
Sixty-seven (60%) of the 111 non-smoking women selected
for this study were from rural villages, and 44 (40%) lived in
the city. The mean age of the study population was 48.5 6
6.7 years, and 86 (78%) were of Turkmen ethnicity.
Adduct levels ranged from 1.7 to 18.6 adducts per
108 nucleotides (Fig. 1) with a median of 5.1 adducts
per 108 nucleotides (IQR: 3.7–7.1). The mean level of ar-
omatic DNA adducts was 5.8 6 3.1 adducts per 108
nucleotides.
As Table 2 shows, in the univariate analyses, the levels of
aromatic DNA adducts were signiﬁcantly lower in homozy-
gotes for at least one N-acetyltransferase 2 (NAT2) slow allele
and in individuals with the excision repair cross-comple-
menting 5 (ERCC5) non-risk-allele genotype, and were higher
in individuals with the myeloperoxidase (MPO) homozygous
risk-allele genotype (homozygous carriers of the -463G al-
lele). The multivariate model to predict adduct level as the
outcome included all of the genes in one group (Phase I,
Phase II, or repair), and was adjusted for the total of risk-al-
lele scores for the other groups, plus the environmental varia-
bles. None of the environmental factors showed a signiﬁcant
association with adduct levels in the multivariate model. Cre-
atinin-adjusted 1-OHPG, a short-term marker of environ-
mental exposure, also did not show a signiﬁcant association
with adduct levels (data not shown). In the adjusted model,
the same genes had a signiﬁcant effect on the adduct level
(Table 2): MPO (b ¼ 0.21; p ¼ 0.01), NAT2 (b ¼ 0.24; p
¼ 0.01), and ERCC5 (b ¼ 0.16; p ¼ 0.04). The sum of the
risk allele scores in these three genes also had a signiﬁcant
linear correlation with the log-adduct level (r ¼ 0.4, p <
0.001).
NER capacity could be measured in 81 individuals. In
these individuals, mean NER capacity was 0.83 6 0.68 (arbi-
trary units) and ranged between 0 and 2.49. As Table 3
shows, the homozygote non-risk-allele MTHFR genotype was
signiﬁcantly associated with lower NER capacity. MTHFR CA
haplotype also showed a signiﬁcant association with NER
capacity (Supporting Information Table 2). Also, homozy-
gotes for risk-allele genotype in ERCC1 had a higher NER
capacity. NER capacity itself did not have a signiﬁcant associ-
ation with the DNA adduct level (data not shown).
Figure 1. Distribution of PAH-related DNA adduct levels among
111 female non-smokers in the Golestan Cohort Study. [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Table 2. Univariate and multivariate analyses of the association between the combined risk allele score in each gene and PAH-DNA adduct
levels
Median adduct (IQR) by risk allele scores1 Adjusted model2
Set Gene 0 1 2 b p Value
Phase I CYP1A1 5.0 (3.7–7.1) 5.3 (4.0–6.5) 9.2 (9.2–9.2) 0.04 0.73
CYP1A2 4.4 (3.6–6.0) 5.4 (4.4–7.1) 5.2 (3.3–7.3) 0.05 0.54
CYP1B1 5.4 (4.1–7.0) 5.2 (3.7–7.2) 4.4 (3.6–5.3) 0.13 0.15
CYP2E1 5.1 (3.8–7.1) 5.7 (3.7–7.1) 4.3 (3.3–5.4) 0.10 0.48
CYP3A4 5.2 (3.8–7.1) 4.4 (4.0–5.5) – 0.20 0.43
mEH 5.5 (3.0–7.1) 4.5 (3.9–6.1) 5.2 (3.3–7.6) 0.01 0.91
MPO 4.3 (2.7–5.9) 4.4 (3.2–6.0) 5.3 (4.2–7.3)3 0.21 0.01
Phase II GPX1 5.1 (3.8–7.4) 5.2 (3.7–6.3) 4.3 (2.3–6.7) 0.08 0.36
GSTM1 5.1 (3.3–7.1) – 5.1 (4.2–7.1) 0.01 0.84
GSTT1 5.2 (3.7–7.0) – 5.1 (3.8–7.1) 0.01 0.88
GSTP1 5.3 (3.7–7.1) 5.0 (3.8–7.1) 5.5 (3.9–6.0) 0.09 0.29
NAT2 6.9 (2.9–7.6) 5.3 (4.1–7.2) 4.2 (2.7–5.3)3 0.24 0.01
NQO1 5.3 (3.8–7.2) 5.1 (3.7–6.7) 4.6 (2.3–7.0) 0.12 0.20
MnSOD2 4.2 (3.7–5.3) 6.0 (4.4–7.7) 4.4 (3.3–5.6) 0.04 0.65
Repair APEX1 5.1 (3.7–5.7) 5.2 (4.0–7.1) 5.1 (3.2–7.1) 0.01 0.97
ERCC1 5.0 (4.5–5.5) 5.1 (3.6–7.1) 5.3 (4.1–7.1) 0.02 0.86
ERCC5 4.4 (2.8–6.1)3 5.2 (4.0–7.1) 6.0 (4.1–7.3) 0.16 0.04
ERCC6 5.0 (4.0–7.0) 5.3 (3.6–7.1) 5.0 (2.7–7.7) 0.09 0.31
MTHFR 5.3 (3.3–7.1) 4.8 (3.7–6.7) 5.4 (3.9– 7.1) 0.10 0.18
RAD23B 5.2 (3.8–7.1) 4.5 (3.6–6.7) 5.1 (3.7–8.9) 0.12 0.26
XPA 4.5 (3.5–6.4) 5.5 (4.0–7.6) 5.4 (3.7–6.7) 0.06 0.50
XPC 4.7 (4.1–5.7) 5.1 (3.9–7.1) 5.3 (3.6–7.0) 0.01 0.90
1score 2: at least one SNP in the gene was homozygous for the risk allele; score 1: at least one SNP in the gene was heterozygous and none were
homozygous for the risk allele;score 0: all of the SNPs in the gene had low-risk alleles.
2The model for polymorphisms in each group was adjusted for environmental exposures and the sum of risk allele scores for other groups.
3p > 0.05 comparing log-transformed adduct levels in one risk score category versus the other two
Abbreviation: IQR: inter-quartile range.
Table 3. Association between the combined risk allele score in repair genes and nucleotide excision repair (NER) capacity
Median NER capacity (IQR) by risk allele scores1
Gene 0 1 2
APEX1 1.13 (0.73–1.26) 0.50 (0.29–1.04) 0.87 (0.42–1.42)
ERCC1 0.80 (0.56–2.03) 0.49 (0.17–1.10) 0.99 (0.60–1.20)2
ERCC5 0.56 (0.07–1.10) 0.75 (0.33–1.27) 0.57 (0.49–1.04)
ERCC6 0.61 (0.27–1.04) 0.61 (0.29–1.26) 1.19 (0.52–2.03)
MTHFR 0.36 (0.17–0.86)2 0.80 (0.44–1.20) 0.81 (0.33–1.42)
RAD23B 0.80 (0.27–1.42) 0.61 (0.33–1.10) 0.78 (0.37–1.19)
XPA 0.50 (0.14–0.99) 0.88 (0.42–1.42) 0.85 (0.40–1.04)
XPC 1.33 (0.44–2.21) 0.59 (0.32–1.20) 0.81 (0.30–1.12)
1score 2: At least one SNP in the gene was homozygous for the risk allele; score 1: at least one SNP in the gene was heterozygous and none were
homozygous for the risk allele; score 0: all of the SNPs in the gene had low-risk alleles.
2p < 0.05 comparing log-transformed NER capacity in one risk score category versus the other two.
Abbreviation: IQR: inter-quartile range.
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In general, the models including phenotypically assessed
NER capacity had a considerably better ﬁt than the models
without it. As Table 4 shows, the model that best ﬁt the data
(as evidenced by the lowest AIC) was the one including the
environmental factors, Phase I enzymes and NER capacity.
This model had an r2 of 0.24, and compared with the 0.07 r2
of the model including environmental model, it could explain
17% more of the variation in DNA adduct levels. The model
deteriorated slightly when the Phase II genes were added.
Also, the models had a better ﬁt when phenotypically
assessed NER was used instead of the polymorphisms in
repair genes.
Discussion
In this study we observed high levels of PAH-related DNA
adducts, with substantial inter-individual variation. The
model including Phase I gene variant scores and measured
NER capacity seemed to explain this variability better than
other models, although individual SNPs from Phase I, Phase
II and repair genes also showed signiﬁcant associations with
adduct levels.
In our study, mean aromatic DNA adduct level was 5.8 6
3.1 adducts per 108 nucleotides. These ﬁndings are in line
with previous ﬁndings of a very high level of exposure to
PAH in this region.3 The source of this high PAH exposure
is not very well understood, but studies suggest that food,
and its method of preparation might play a role.8 In any
case, we ruled out external contamination by careful quality
control of sample collection and processing. In Dutch smok-
ers, the mean DNA adduct level has been reported to be 1.40
6 0.79 adducts per 108 nucleotides, with a range between
0.25 and 3.90.14 Binkova et al. reported PAH adducts in sev-
eral occupationally-exposed groups, such as Czech and Slovak
coke-oven workers, and even among the smokers in these
groups, they observed levels much lower than those in the
present study.29,30 In another study of occupationally-exposed
workers from China, another country with a high rate of
esophageal squamous cell carcinoma, the highest mean PAH-
related DNA adduct level, among coke oven workers, was
1.66 6 0.21 adducts per 108 nucleotides.31 All these adduct
levels were measured using 32P-postlabeling, and variations in
postlabeling results from different laboratories may contribute
to some of these differences. Nevertheless, both our measure-
ments and those in the Dutch study were done in laborato-
ries which participated in a study to make postlabeling proto-
cols more uniform across Europe, which signiﬁcantly
improved assay reliability in the participating laboratories.32
In general, 32P-postlabeling has proven to be a relatively reli-
able method for measuring aromatic DNA adducts, and has
improved over the years,33 and in our study, we observed a
good assay CV (10.2%) in the duplicate samples.
Measurement of DNA adducts can be considered as an
intermediate marker of cancer risk, which reﬂects the bio-
logically effective dose of PAH exposure.30,34 As in our
study, however, SNPs in some individual genes may not
show signiﬁcant associations with DNA adduct levels, de-
spite the crucial role of these genes in coding enzymes
which metabolize PAHs. This low level of association may
be caused by several factors including a large degree of vari-
ation in environmental exposures and unmeasured factors
which affect adduct levels, and insufﬁcient power of the
study due to the low frequency of the studied polymor-
phisms. In this setting, model comparison using information
criteria such as AIC offers two advantages over traditional
hypothesis-testing: ﬁrst it does not rely on a predeﬁned sig-
niﬁcance level, and its power in determining the best model
is not dependent on study power or sample size.35 In gen-
eral, if the difference between the AIC of the ‘‘best’’ model
and other models is more than 2, the model has consider-
able support, and if this difference is above 10, this support
is very strong.35 In our study, models with NER capacity
had the highest AIC difference, followed by those including
Phase 1 enzymes. To the best of our knowledge, this is the
ﬁrst study showing the importance of NER phenotyping in
predicting aromatic DNA adduct levels. Compared with
genotyping, repair phenotyping provides a better indication
of the cells’ enzymatic repair capacity.17
The second advantage of AIC, is that it assesses the whole
model rather than its individual components. In the present
study we found signiﬁcant results for only one of the Phase I
genes, and the effect of NER capacity on DNA adduct levels
was not signiﬁcant by itself, but these two together comprised
Table 4. Comparison of different models in predicting DNA adduct
levels
Variables in the Model1 AIC
Environmental 156.33
Environmental þ 1-ohpg 157.84
Environmentalþ phase I polymorphisms 151.19
Environmentalþ phase II polymorphisms 157.10
Environmental þ phase I and phase II
polymorphisms
154.57
Environmental þ repair genes 160.68
Environmental þ phase I polymorphisms þ
repair genes
157.49
Environmental þ phase I and phase II
polymorphisms þ repair genes
158.79
Environmental þ NER capacity 102.66
Environmental þ phase I polymorphisms þ
NER capacity
100.07
Environmental þ phase II polymorphisms þ
NER capacity
105.02
Environmental þ phase I and phase II
polymorphisms þ NER capacity
106.50
1The base model included only environmental factors; other models
were built by adding one group of variables at a time to the base
model.
Abbreviations: AIC: Akaike’s information criterion (lower AIC indicates a
better fit of the model); NER: nucleotide excision repair.
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the best model. This underlines the importance of a compre-
hensive approach to evaluating pathways affecting cancer risk
or carcinogenic metabolism. One of the approaches proposed
for such analysis is the consideration of simultaneous genetic
variations in multiple genes.36 In a study on 170 healthy vol-
unteers, Butkiewicz et al.37 showed that although a GSTP1
polymorphism alone was not associated with a change in
DNA adduct level, when combined with GSTM1 deletion, it
was associated with increased adduct formation. Georgiadis
et al.38 also used a similar combination method, and showed
a synergistic effect between Phase I and Phase II genes. The
limitation of such an approach is that with increasing num-
bers of genes, and polymorphisms within each gene, interpre-
tation becomes very complicated as the number of different
possible combinations increases dramatically.
In a different approach, the total number of risk alleles can
be used to summarize the genetic risk proﬁle of an individual.
Ketelslegers et al. used this method and observed an association
between the number of risk alleles and DNA adduct levels in
smokers.14 The sum of three risk alleles in their study (GSTM1,
mEH and GPX) was associated with a twofold increase in adduct
level. We used the same approach for three different genes
(MPO, NAT2 and ERCC5) and observed a linear association.
We also adopted a gene-based approach by combining the poly-
morphic alleles in each gene, which were known to act in the
same direction and were in linkage disequilibrium, and used
modeling to identify the combination of different alleles that
could best explain variability in adduct levels. In this way, SNPs
in Phase I genes appeared to inﬂuence DNA adduct formation
more than SNPs in Phase II genes. Agudo et al.39 also used a
multivariate regression model in the EPIC-Spain cohort and
deﬁned ‘‘imputed phenotypes’’ based on the combinations of ge-
notypes in deﬁned pathways. They observed signiﬁcant changes
in DNA adduct levels caused by combined oxidation-hydrolysis
(Phase I enzymes), acetylation (NAT2), and oxidation-acetyla-
tion pathways, which is in line with our ﬁndings. Abnet et al.40
studied a group of individuals from another ESCC high-risk
area in Brazil, using a multivariate approach. They showed that
adding Phase I polymorphisms to environmental exposures
increased the ability of the model to predict 1-OHPG concentra-
tion by 12%. A biomarker, 1-OHPG, has been extensively used
to evaluate PAH exposure in general population and occupa-
tional groups. This marker, however, has a short half-life and
may not be suitable for studying the long-term carcinogenic
effects of PAHs and their metabolites.40 In our study, 1-OHPG
was not associated with the adduct level and did not improve
adduct formation model ﬁt.
We found several interesting associations with individual
genes. The ﬁnding that MPO genotype inﬂuences PAH-
related DNA adducts is consistent in the literature and is
related both to its important role in the benzo-[a]pyrene
(BaP) activation as a result of oxidation of B[a]P to BaP-7,8-
diol and ultimately BPDE,41,42 and to its ability to diminish
DNA repair via the local production of hypochlorous acid
(HOCl) at inﬂammation sites.43,44 Rojas et al.45 showed that
BPDE-DNA adduct formation was decreased in the skin of
coal-tar treated patients carrying the MPO mutant allele. In
another study, this polymorphism was shown to reduce DNA
adduct levels in bronchoalveolar lavage specimens from
smokers.46
Studies on the effects of NAT2 polymorphisms on adduct
formation have had different results. Godschalk et al.10
showed a lower level of DNA adducts in the fast-acetylation
group. In contrast, in the EPIC-Spain cohort, slow acetylation
by NAT2 was associated with a signiﬁcantly decreased adduct
level in healthy adults,39 similar to our results. Lee et al.47
showed that slow acetylation was associated with increased
DNA adducts in the lung, but a non-signiﬁcant reduction of
adducts in the blood monocytes of lung cancer patients. Sub-
strate-speciﬁc action of NAT has been proposed as a possible
reason for such differences.39
Some of the repair genes also showed associations with ei-
ther DNA adduct level or NER capacity. ERCC-5 was the
only repair gene in our data which had a signiﬁcant effect on
DNA adduct level. The ERCC-5 C/C genotype which was
associated with increased adduct level in our study, has been
shown to increase the risk of lung cancer.48 We also showed
that NER capacity itself is increased in individuals with
MTHFR and ERCC1 polymorphisms. Two of the SNPs we
studied in the ERCC1 gene (rs11615 T allele and rs3212986
C allele) have been shown to increase DNA adduct levels,49
but this is the ﬁrst study to show the association between
this gene and NER capacity.
Although the role of MTHFR in DNA repair may not be
straightforward, it has been shown that the rs1801133
MTHFR T allele could increase 5,10-methylenetetrahydrofo-
late levels, which is necessary for DNA repair.50 Choi
et al.51 have shown reduced excision repair in folate-
depleted rats. However, unlike our assay, which quantiﬁes
the comet formation due to single-strand breaks, this
reduced repair was reﬂected by the slowed recovery of the
damage-induced comets as a result of insufﬁcient thymidy-
late and purine production. Besides it is not clear how
much dietary intake, in the ranges higher than the depletion
investigated in Choi’s study, can affect DNA repair. We did
not measure folate intake in our study to further investigate
the possibility of such an association, and it is unlikely that
our study population had a very heterogeneous pattern of
folate intake.
This study has one of the largest sets of PAH metaboliz-
ing and repair genes that have been studied together, and it
combines repair phenotyping and genotyping in one study.
Also, almost all previous studies, unlike the present one, have
included only smokers or groups with occupational expo-
sures. Given the importance of PAH exposure in non-smok-
ers and its relevance to ESCC and lung cancer, this study can
contribute to our understanding of PAH-related carcinogene-
sis in this group. One of the limitations of this study is its
relatively small sample size. So, as in many similar studies,
the sample size did not allow more sophisticated pathway
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analyses, and may have been the reason for the lack of asso-
ciation between NER capacity and adduct levels. We also did
not study more genes in the pathway, which might explain
some of the remaining 76% of the variation in the adduct
level, and had to assume linearity of effects when using
regression models, which is not necessarily the case.
In conclusion, we have observed high levels of PAH-
related DNA adducts in female non-smokers in this popula-
tion, and found interesting associations between MPO, NAT2
and ERCC5 polymorphisms and DNA adduct levels. We
have also shown the importance of studying combined
genetic polymorphisms and NER phenotyping when studying
cancer risk in relation to PAH exposure. Finally, we have
shown that inter-individual variation in adduct levels could
best be explained by a combination of polymorphisms in
Phase I genes and NER capacity.
References
1. Baan R, Grosse Y, Straif K, et al. A review of
human carcinogens–Part F: chemical agents and
related occupations. Lancet Oncol 2009;10:1143–4.
2. Abedi-Ardekani B, Kamangar F, Hewitt SM, et al.
Polycyclic aromatic hydrocarbon exposure in
oesophageal tissue and risk of oesophageal
squamous cell carcinoma in north-eastern Iran.
Gut 2010;59:1178–83.
3. Kamangar F, Strickland PT, Pourshams A, et al.
High exposure to polycyclic aromatic
hydrocarbons may contribute to high risk of
esophageal cancer in northeastern Iran.
Anticancer Res 2005;25:425–8.
4. Fagundes RB, Abnet CC, Strickland PT, et al.
Higher urine 1-hydroxy pyrene glucuronide (1-
OHPG) is associated with tobacco smoke
exposure and drinking mate in healthy subjects
from Rio Grande do Sul, Brazil. BMC Cancer
2006;6:139.
5. Wornat MJ, Ledesma EB, Sandrowitz AK, et al.
Polycyclic aromatic hydrocarbons identiﬁed in
soot extracts from domestic coal-burning stoves
of Henan Province, China. Environ Sci Technol
2001;35:1943–52.
6. Roth MJ, Qiao YL, Rothman N, et al. High urine
1-hydroxypyrene glucuronide concentrations in
Linxian, China, an area of high risk for
squamous oesophageal cancer. Biomarkers 2001;6:
381–6.
7. Roth MJ, Strickland KL, Wang GQ, et al. High
levels of carcinogenic polycyclic aromatic
hydrocarbons present within food from Linxian,
China may contribute to that region’s high
incidence of oesophageal cancer. Eur J Cancer
1998;34:757–8.
8. Hakami R, Mohtadinia J, Etemadi A, et al.
Dietary intake of benzo(a)pyrene and risk of
esophageal cancer in north of Iran. Nutr Cancer
2008;60:216–21.
9. Samet JM, Avila-Tang E, Boffetta P, et al. Lung
cancer in never smokers: clinical epidemiology
and environmental risk factors. Clin Cancer Res
2009;15:5626–45.
10. Godschalk RW, Dallinga JW, Wikman H, et al.
Modulation of DNA and protein adducts in
smokers by genetic polymorphisms in
GSTM1,GSTT1, NAT1 and NAT2.
Pharmacogenetics 2001;11:389–98.
11. Phillips DH. DNA adducts as markers of
exposure and risk. Mutat Res 2005;577:284–92.
12. Ishikawa T, Zhang SS, Qin X, et al. DNA repair
and cancer: lessons from mutant mouse models.
Cancer Sci 2004;95:112–17.
13. Godschalk RW, Van Schooten FJ, Bartsch H. A
critical evaluation of DNA adducts as biological
markers for human exposure to polycyclic
aromatic compounds. J Biochem Mol Biol 2003;
36:1–11.
14. Ketelslegers HB, Gottschalk RW, Godschalk RW,
et al. Interindividual variations in DNA adduct
levels assessed by analysis of multiple genetic
polymorphisms in smokers. Cancer Epidemiol
Biomarkers Prev 2006;15:624–9.
15. Pourshams A, Khademi H, Malekshah AF, et al.
Cohort proﬁle: the Golestan cohort Study–a
prospective study of oesophageal cancer in
northern Iran. Int J Epidemiol 2010;39:52–9.
16. Boyum A. Isolation of lymphocytes, granulocytes
and macrophages. Scand J Immunol 1976;Suppl 5:
9–15.
17. Hirvonen A. State of the art of genotype vs.
phenotype studies. Environmental Cancer Risk,
Nutrition and Individual Susceptibility (ECNIS).
Lodz: Nofer Institute of Occupational Medicine,
2008. 98 p.
18. Knaapen AM, Ketelslegers HB, Gottschalk RW,
et al. Simultaneous genotyping of nine
polymorphisms in xenobiotic-metabolizing
enzymes by multiplex PCR ampliﬁcation and
single base extension. Clin Chem 2004;50:1664–8.
19. Langie SA, Wilms LC, Hamalainen S, et al.
Modulation of nucleotide excision repair in
human lymphocytes by genetic and dietary
factors. Br J Nutr 2010;103:490–501.
20. Hansen WK, Kelley MR. Review of mammalian
DNA repair and translational implications. J
Pharmacol Exp Ther 2000;295:1–9.
21. Langie SA, Knaapen AM, Brauers KJ, et al.
Development and validation of a modiﬁed comet
assay to phenotypically assess nucleotide excision
repair. Mutagenesis 2006;21:153–8.
22. Redaelli A, Magrassi R, Bonassi S, et al. AP
endonuclease activity in humans: development of
a simple assay and analysis of ten normal
individuals. Teratog Carcinog Mutagen 1998;18:
17–26.
23. Knaapen AM, Schins RP, Borm PJ, et al. Nitrite
enhances neutrophil-induced DNA strand
breakage in pulmonary epithelial cells by
inhibition of myeloperoxidase. Carcinogenesis
2005;26:1642–8.
24. Strickland PT, Kang D, Bowman ED, et al.
Identiﬁcation of 1-hydroxypyrene glucuronide as
a major pyrene metabolite in human urine by
synchronous ﬂuorescence spectroscopy and gas
chromatography-mass spectrometry.
Carcinogenesis 1994;15:483–7.
25. Phillips DH, Arlt VM. The 32P-postlabeling assay
for DNA adducts. Nat Protoc 2007;2:2772–81.
26. Ketelslegers HB, Gottschalk RW, Koppen G, et al.
Multiplex genotyping as a biomarker for
susceptibility to carcinogenic exposure in the
FLEHS biomonitoring study. Cancer Epidemiol
Biomarkers Prev 2008;17:1902–12.
27. Walker K, Ginsberg G, Hattis D, et al. Genetic
polymorphism in N-acetyltransferase (NAT):
population distribution of NAT1 and NAT2
activity. J Toxicol Environ Health B Crit Rev
2009;12:440–72.
28. Bozdogan H. Akaike’s information criterion and
recent developments in information complexity. J
Math Psychol 2000;44:62–91.
29. Binkova B, Topinka J, Mrackova G, et al. Coke
oven workers study: the effect of exposure and
GSTM1 and NAT2 genotypes on DNA adduct
levels in white blood cells and lymphocytes as
determined by 32P-postlabelling. Mutat Res 1998;
416:67–84.
30. Binkova B, Chvatalova I, Lnenickova Z, et al.
PAH-DNA adducts in environmentally exposed
population in relation to metabolic and DNA
repair gene polymorphisms. Mutat Res 2007;620:
49–61.
31. Hu Y, Li G, Xue X, et al. PAH-DNA adducts in a
Chinese population: relationship to PAH
exposure, smoking and polymorphisms of
metabolic and DNA repair genes. Biomarkers
2008;13:27–40.
32. Phillips DH, Castegnaro M. Standardization and
validation of DNA adduct postlabelling methods:
report of interlaboratory trials and production of
recommended protocols. Mutagenesis 1999;14:
301–15.
33. Gallo V, Khan A, Gonzales C, et al. Validation of
biomarkers for the study of environmental
carcinogens: a review. Biomarkers 2008;13:
505–34.
34. Brandt HC, Watson WP. Monitoring human
occupational and environmental exposures to
polycyclic aromatic compounds. Ann Occup Hyg
2003;47:349–78.
35. Burnham KP, Anderson DR. Model selection and
multimodel inference: a practical information-
theoretic approach, 2nd edn. New York: Springer,
2002.
36. Alexandrov K, Cascorbi I, Rojas M, et al.
CYP1A1 and GSTM1 genotypes affect
benzo[a]pyrene DNA adducts in smokers’
lung: comparison with aromatic/hydrophobic
adduct formation. Carcinogenesis 2002;23:
1969–77.
37. Butkiewicz D, Grzybowska E, Phillips DH, et al.
Polymorphisms of the GSTP1 and GSTM1 genes
and PAH-DNA adducts in human mononuclear
white blood cells. Environ Mol Mutagen 2000;35:
99–105.
38. Georgiadis P, Demopoulos NA, Topinka J, et al.
Impact of phase I or phase II enzyme
polymorphisms on lymphocyte DNA adducts in
subjects exposed to urban air pollution and
environmental tobacco smoke. Toxicol Lett 2004;
149:269–80.
39. Agudo A, Peluso M, Sala N, et al. Aromatic
DNA adducts and polymorphisms in metabolic
C
ar
ci
n
og
en
es
is
Etemadi et al. 9
Int. J. Cancer: 000, 000–000 (2012) VC 2012 UICC
genes in healthy adults: ﬁndings from the
EPIC-Spain cohort. Carcinogenesis 2009;30:
968–76.
40. Abnet CC, Fagundes RB, Strickland PT, et al.
The inﬂuence of genetic polymorphisms in Ahr,
CYP1A1, CYP1A2, CYP1B1, GST M1, GST T1
and UGT1A1 on urine 1-hydroxypyrene
glucuronide concentrations in healthy subjects
from Rio Grande do Sul, Brazil. Carcinogenesis
2007;28:112–17.
41. Petruska JM, Mosebrook DR, Jakab GJ, et al.
Myeloperoxidase-enhanced formation of (þ-)-trans-
7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene-DNA
adducts in lung tissue in vitro: a role of pulmonary
inﬂammation in the bioactivation
of a procarcinogen. Carcinogenesis 1992;13:1075–81.
42. Knaapen AM, Gungor N, Schins RP, et al.
Neutrophils and respiratory tract DNA damage
and mutagenesis: a review. Mutagenesis 2006;21:
225–36.
43. Gungor N, Godschalk RW, Pachen DM, et al.
Activated neutrophils inhibit nucleotide excision
repair in human pulmonary epithelial cells: role
of myeloperoxidase. FASEB J 2007;21:2359–67.
44. Gungor N, Haegens A, Knaapen AM, et al. Lung
inﬂammation is associated with reduced
pulmonary nucleotide excision repair in vivo.
Mutagenesis 2010;25:77–82.
45. Rojas M, Godschalk R, Alexandrov K, et al.
Myeloperoxidase–463A variant reduces
benzo[a]pyrene diol epoxide DNA adducts in
skin of coal tar treated patients. Carcinogenesis
2001;22:1015–18.
46. Van Schooten FJ, Boots AW, Knaapen AM, et al.
Myeloperoxidase (MPO) -463G->A reduces MPO
activity and DNA adduct levels in
bronchoalveolar lavages of smokers. Cancer
Epidemiol Biomarkers Prev 2004;13:828–33.
47. Lee MS, Su L, Christiani DC. Synergistic
effects of NAT2 slow and GSTM1 null
genotypes on carcinogen DNA damage in the
lung. Cancer Epidemiol Biomarkers Prev 2010;
19:1492–7.
48. Kiyohara C, Yoshimasu K. Genetic
polymorphisms in the nucleotide excision repair
pathway and lung cancer risk: a meta-analysis.
Int J Med Sci 2007;4:59–71.
49. Lee MS, Su L, Mark EJ, et al. Genetic
modiﬁers of carcinogen DNA adducts in
target lung and peripheral blood
mononuclear cells. Carcinogenesis 2010;31:
2091–6.
50. Ma J, Stampfer MJ, Giovannucci E, et al.
Methylenetetrahydrofolate reductase
polymorphism, dietary interactions, and
risk of colorectal cancer. Cancer Res 1997;57:
1098–102.
51. Choi SW, Kim YI, Weitzel JN, et al. Folate
depletion impairs DNA excision repair in the
colon of the rat. Gut 1998;43:93–9.
C
ar
ci
n
og
en
es
is
10 Determinants of PAH-DNA adducts in non-smokers
Int. J. Cancer: 000, 000–000 (2012) VC 2012 UICC
